Cefdinir: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Cefdinir. Educational only — not medical advice.

Reported adverse reactions

ReactionHighest frequency reported*
Incidence ≥ 1%8%
Rash3%
Vomiting1%
↓bicarbonate1%
↑eosinophils1%
↑lactate dehydrogenase1%
↑platelets1%
↑urine protein1%
Incidence < 1% but > 0.1%0.9%
Abdominal pain0.8%
↑urine ph0.8%
↓calcium0.5%
↓hemoglobin0.5%
↑urine leukocytes0.5%
↑monocytes0.4%
Leukopenia0.3%
↑ast0.3%
↑potassium0.3%
Hyperkinesia0.2%
Increased ast0.2%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir for oral suspension USP and other antibacterial drugs, cefdinir for oral suspension USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension USP is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia Caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (seeCLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis Caused by Haemophilus influe…

Source: FDA labeling via NIH DailyMed (set 7640dd80…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.